Interactions between traditional Chinese medicines and Western therapeutics

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 1, 2010, Pages 50-65

  Chan, Elena ^a   Tan, Marisela ^a   Xin, Jianni ^a   Sudarsanam, Sucha ^b   Johnson, Dale E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Emiliem Inc   (United States)

Author keywords

GeneGo; Herb drug interaction; MetaDrug; Phytochemical; Quantitative structure activity relationship; TCM; Traditional Chinese medicine

Indexed keywords

AMFEBUTAMONE; AMODIAQUINE; BLACK PEPPER EXTRACT; BOSWELLIA CARTERIL EXTRACT; CLOZAPINE; CYCLOBENZAPRINE; CYCLOPHOSPHAMIDE; ECHINACEA PURPUREA EXTRACT; EFAVIRENZ; GINKGO BILOBA EXTRACT; GRAPEFRUIT EXTRACT; GREEN TEA EXTRACT; HYPERICUM PERFORATUM EXTRACT; IFOSFAMIDE; IMIPRAMINE; KAVA EXTRACT; MATRICARIA RECUTITA EXTRACT; METHADONE; MEXILETINE; NAPROXEN; PACLITAXEL; PEPPERMINT; PLANT MEDICINAL PRODUCT; RILUZOLE; SCUTELLARIA BAICALENSIS EXTRACT; TACRINE; TARAXACUM OFFICIALE EXTRACT; TARAXACUM OFFICINALE EXTRACT; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHINESE MEDICINE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG USE; EVIDENCE BASED PRACTICE; HEALTH CARE SYSTEM; HERB; HERB DRUG INTERACTION; HUMAN; MEDICINE; MULTICENTER STUDY; NONHUMAN; REVIEW; TEA; WESTERN MEDICINE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DATABASES, FACTUAL; DRUG AND NARCOTIC CONTROL; DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; STRUCTURE-ACTIVITY RELATIONSHIP; WESTERN WORLD;

EID: 73849123558     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Foster BC, Arnason JT, Briggs CJ: Natural health products and drug disposition. Annu Rev Pharmacol Toxicol (2005) 45:203-226.
2. Bent S: Herbal medicine in the United States: Review of efficacy, safety, and regulation: Grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med (2008) 23(6):854-859.
3. Thomson Reuters: Alternative medicine a big business in US: Report: Thomson Reuters, 3 Times Square, New York, NY 10036, USA (2009). www.reuters.com/article/idUSTRE56T6MN20090730
4. Geng J, Su Z: Practical Traditional Chinese Medicine and Pharmacology: Basic Theories and Principles, New World Press, Beijing, China (1996).
5. National Center for Complementary and Alternative Medicine: NIH, Bethesda, MD, US (2009). nccam.nih.gov
6. Complementary and alternative medicine in the United States: Institute of Medicine of the National Academies, Washington DC, US (2005). www.iom.edu/Reports/2005/Complementary-and- Alternative-Medicine-in-the-United- States.aspx
7. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbano TL: Unconventional medicine in the United States. Prelevance, costs, and patterns of use. N Engl J Med (1993) 328(4):246-252.
8. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC: Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA (1998) 280(18):1569-1575.
9. Barnes PM, Powell-Griner E, McFann K, Nahin R: Complementary and alternative medicine use among adults: United States, 2002. Semin Integrative Med (2004) 2(2):54-71.
10. Osher Center for Integrative Medicine: University of California, San Francisco, CA, US (2009). www.osher.ucsf.edu
11. UCLA Collaborative Centers for Integrative Medicine: University of California, Los Angeles, CA, US (2009). www.ccim.med.ucla.edu
12. Wong KC, Lien-Teh W (Eds): History of Chinese Medicine. National Quarantine Service, Shanghai, China (1936).
13. He S, Song K, Su Z (Eds): Chronotherapy and Chronopharmacotherapy. Tianjin Science and Technology Press, Tianjin, China (1994).
14. Ko KM, Mak DH, Chiu PY, Poon MK: Pharmacological basis of 'Yang-invigoration' in Chinese medicine. Trends Pharmacol Sci (2004) 25(1):3-6.
15. Zhu Y, Woerdenbag HJ: Traditional Chinese herbal medicine. Pharmacy World Sci (1995) 17(4):103-112.
16. Liao H, Banbury LK, Leach DN: Antioxidant activity of 45 Chinese herbs and the relationship with their TCM characteristics. Evid Based Complement Alternat Med (2008) 5(4):429-434.
17. Sagar SM, Wong RK: Chinese medicine and biomodulation in cancer patients (Part one). Curr Oncol (2008) 15(1):42-48.
18. Chen X, Zhou H, Liu YB, Wang JF, Li H, Ung CY, Han LY, Cao ZW, Chen YZ: Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation. Br J Pharmacol (2006) 149(8):1092-1103.
19. Ma XH, Zheng CJ, Han LY, Xie B, Jia J, Cao ZW, Li YX, Chen YZ: Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. Drug Discov Today (2009) 14(11-12):579-588.
20. Klein G: Cancer, apoptosis, and nonimmune surveillance. Cell Death Differ (2004) 11(1):13-17.
21. Li BQ, Fu T, Gong WH, Dunlop N, Kung H, Yan Y, Kang J, Wang JM: The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacology (2000) 49(3):295-306.
22. Pidgeon G, Kandouz M, Meram A, Honn KV: Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res (2002) 62(9):2721-2727.
23. Yance DR Jr, Sagar SM: Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther (2006) 5(1):9-29.
24. Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, Hui CK, Lau GK, Fan ST: Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: From laboratory discovery to clinical evaluation. Liver Int (2007) 27(7):879-890.
25. Parekh HS, Liu G, Wei MQ: A new dawn for the use of traditional Chinese medicine in cancer therapy. Mol Cancer (2009) 8:21.
26. A joint consultation on the Report to Ministers from the DH Steering Group on the statutory regulation of practitioners of acupuncture, herbal medicine, Traditional Chinese Medicine, and other traditional medicine systems practiced in the UK: Department of Health, Leeds, UK (2009). www.dh.gov.uk/eu/ consultations/liveconsultations/dh-103567
27. Nakao M, Muramoto Y, Hisadome M, Yamano N, Shoji M, Fukushima Y, Saruwatari J, Nakagawa K: The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6. Eur J Clin Pharmacol (2007) 63(4):345-353.
28. Shohet D, Wills RB, Stuart DL: Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie (2001) 56(11):860-863.
29. Palá-Paúl J, Pérez-Alonso MJ, Velasco-Negueruela A, Palá-Paúl R, Sanz J, Conejero F: Seasonal variation in chemical constituents of Santolina rosmarinifolia L ssp rosmarinifolia. Biochem Syst Ecol (2001) 29(7):663-672.
30. Southwell I, Bourke C: Seasonal variation in hypericin content of Hypericum perforatum L (St John's wort). Phytochemistry (2001) 56:437-441.
31. Westerhoff K, Kaunzinger A, Wurglics M, Dressman J, Schubert- Zsilavecz M: Biorelevant dissolution testing of St John's wort products. J Pharm Pharmacol (2002) 54(12):1615-1621.
32. Jürgenliemk G, Nahrstedt A: Dissolution, solubility and cooperativity of phenolic compounds from Hypericum perforatum L in aqueous systems. Pharmazie (2003) 58(3):200-203.
33. Taglioli V, Bilia AR, Ghiara C, Mazzi G, Mercati V, Vincieri FF: Evaluation of the dissolution behaviour of some commercial herbal drugs and their preparations. Pharmazie (2001) 56(11):868-870.
34. Fugh-Berman A: Herb-drug interactions. Lancet (2000) 355(9198):134-138.
35. Zou L, Harkey M, Henderson G: Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products. Phytomedicine (2002) 9(3):263-267.
36. Stone R: Biochemistry. Lifting the veil on traditional Chinese medicine. Science (2008) 319(5864):709-710.
37. Ji H, Li X, Zhang H: Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep (2009) 10(3):194-200.
38. Ehrman TM, Barlow DJ, Hylands PJ: Phytochemical informatics of traditional Chinese medicine and therapeutic relevance. J Chem Inf Model (2007) 47(6):2316-2334.
39. Zhou L, Zuo Z, Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol (2005) 45(12):1345-1359.
40. Tang Y, Garg H, Geng YJ, Bryan NS: Nitric oxide bioactivity of traditional Chinese medicines used for cardiovascular indications. Free Radic Biol Med (2009) 47(6):835-840.
41. Lundberg JO, Weitzberg E, Gladwin MT: The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov (2008) 7(2):156-167.
42. Ehrman TM, Barlow DJ, Hylands PJ: Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specificities. J Chem Inf Model (2007) 47(2):254-263.
43. TCM-ID: National University of Singapore, Department of Computational Science, Singapore (2005). tcm.cz3.nus.edu.sg/ group/tcm-id/tcmid-ns.asp
44. Fang X, Shao L, Zhang H, Wang S: CHMIS-C: A comprehensive herbal medicine information system for cancer. J Med Chem (2005) 48(5):1481-1488.
45. PubChem: US National Center for Biotechnology Information, Bethesda, MD, US (2009). pubchem.ncbi.nlm.nih.gov
46. Entrez Gene: US National Center for Biotechnology Information, Bethesda MD, US (2009). www.ncbi.nlm.nih.gov/gene/
47. ChemFile Browser: Hyleos.net, Saint Dié, France (2009). www. hyleos.net/s=applications&p=ChemFileBrowser
48. The GeneCards human gene database: Weizmann Institute of Science, Rehovot, Israel (2009). www.genecards.org
49. The Universal Protein Knowledge Database: EMBL-EBI, Cambridge, UK; SIB Geneva, Switzerland; PIR, Washington DC, US (2009). www.uniprot.org/uniprot
50. The Kyoto Encyclopedia of Genes & Genomes (KEGG) Pathway Database: Kanehisa Laboratories, Kyoto University, Kyoto, Japan (2009). www.genome.jp/kegg/pathway.html
51. The Pharmacogenomics Knowledge Base: PharmGKB, Stanford University, Palo Alto, CA, US (2009). www.pharmgkb.org
52. Biocarta Pathways: BioCarta LLC, San Diego, CA, US (2009). www. biocarta.com/genes/index.asp
53. yEd Graph Editor: yWorks Gmbh, Tübingen, Germany (2009). www. yworks.com/en/products-yed-about.html
54. MetaDrug: Compound based pathway analysis, system chemical biology. GeneGo Inc, St Joseph, MI, USA (2009). www. genego.com/metadrug.php
55. Chan TY: Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother (2001) 35(4):501-504.
56. Qiu F, Zhang R, Sun J, Jiye A, Hao H, Peng Y, Ai H, Wang G: Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos (2008) 36(7):1308-1314.
57. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov (2002) 1(9):727-730.
58. Zhao AG, Yang JK, You SF, Li T, Zhao HL, Gu Y, Tang LD: Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA. Zhongguo Zhong Yao Za Zhi (2007) 32(19):2028-2036.
59. Zhao KJ, Dong TT, Tu PF, Song ZH, Lo CK, Tsim KW: Molecular genetic and chemical assessment of Radix Angelica (Danggui) in China. J Agric Food Chem (2003) 51(9):2576-2583.
60. Page RL 2nd, Lawrence JD: Potentiation of warfarin by dong quai. Pharmacotherapy (1999) 19(7):870-876.
61. Yang X, Hu Z, Duan W, Zhu Y, Zhou S: Drug-herb interactions: Eliminating toxicity with hard drug design. Curr Pharm Des (2006) 12(35):4649-4664.
62. Drug interactions between Abbokinase and dong quai: Drugs. com, Drugsite Trust, North Shore, Auckland, New Zealand (2009). www.drugs.com/drug- interactions/abbokinase-with-dong-quai-2280- 3882-2366-0.html
63. Dong quai (Angelica sinensis): US National Library of Medicine, Bethesda, MD, USA (2009). www.nlm.nih.gov/medlineplus/druginfo/ natural/patient-dongquai. html
64. Circosta C, Pasquale RD, Palumbo DR, Samperi S, Occhiuto F: Estrogenic activity of standardized extract of Angelica sinensis. Phytother Res (2006) 20(8):665-669.
65. Bensky D (Ed): Chinese Herbal Medicine: Materia Medica, 3rd edition. Eastland Press, Seattle, WA, USA (2004).
66. Shi J: The ABCs of traditional Chinese medicine and acupuncture. Acupuncture Today (1985):1-4.
67. Asl MN, Hosseinzadeh H: Review of pharmacological effects of Glycyrrhiza sp and its bioactive compounds. Phytother Res (2008) 22(6):709-724.
68. Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, Bielenberg J: Antiviral effects of Glycyrrhiza species. Phytother Res (2008) 22(2):141-148.
69. Pompei R, Flore O, Marccialis MA, Pani A, Loddo B: Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature (1979) 281(5733):689-690.
70. Wan X, Luo M, Li X, He P: Hepatoprotective and antihepatocarcinogenic effects of glycyrrhizin and matrine. Chem Biol Interact (2009) 181(1):15-19.
71. Li YW, Yang HZ, Ke QS, Chen W, Chen XJ: [Effects of glycyrrhizin on the expression of hepatitis B virus and Toll like receptors 2,4 in HepG2.2.15 cells expressing low HBsAg]. Zhong Yao Cai (2008) 31(3):403-407.
72. Yao H, Fu X, Xie Q, Huang B, Sun Y, Li G: [Effect of liquorice decoction on rat intestinal P-glycoprotein]. Nan Fang Yi Ke Da Xue Xue Bao (2009) 29(8):1571-1573.
73. Licorice drug interactions: Drugs.com, Drugsite Trust, North Shore, Auckland, New Zealand (2009). www.drugs.com/drug-interactions/ licorice-index.html
74. Flockhart DA: P450 drug interaction table: Abbreviated 'clinically relevant' table: Indiana University School of Medicine, Indianapolis, IN, USA (2007). medicine.iupui.edu/clinpharm/ddis/ clinicalTable.asp
75. Nowack R: Review article: Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: Grapefruit juice, St John's wort - And beyond! Nephrology (2008) 13(4):337-347.
76. Ioannides C: Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica (2002) 32(6):451-478.
77. Hidaka M, Nagata M, Kawano Y, Sekiya H, Kai H, Yamasaki K, Okumura M, Arimori K: Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Biosci Biotechnol Biochem (2008) 72(2):406-411.